PMN Stock Price, ProMIS Neurosciences, . Quote, Chart

Market Summary

USD1.99+0.07

Market Closed

3.65%

PMN Stock Price

View Fullscreen

PMN RSI Chart

PMN Valuation

Market Cap

37.7M

Price/Earnings (Trailing)

-2.86

Price/Free Cashflow

-3.48

PMN Price/Earnings (Trailing)

PMN Profitability

Return on Equity

-352.02%

Return on Assets

-97.01%

Free Cashflow Yield

-28.74%

PMN Fundamentals

PMN Earnings

Earnings (TTM)

-13.2M

Earnings Growth (Yr)

50.72%

Earnings Growth (Qtr)

-51.67%

Breaking Down PMN Revenue

Last 7 days

2.1%

Last 30 days

-11.9%

Last 90 days

-3.9%

How does PMN drawdown profile look like?

PMN Financial Health

Current Ratio

1.46

PMN Investor Care

Shares Dilution (1Y)

121.01%

Diluted EPS (TTM)

-1.1

Tracking the Latest Insider Buys and Sells of ProMIS Neurosciences, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 23, 2023	farfel gail m	acquired	-	-	53,192	chief executive officer
Aug 23, 2023	milbury max a.	acquired	-	-	13,297	principal accounting officer
Aug 23, 2023	malenfant gavin t.	acquired	-	-	2,660	chief operating officer
Aug 23, 2023	kirwin patrick d.	acquired	-	-	11,000	-
Aug 23, 2023	cashman neil	acquired	-	-	10,643	chief scientific officer
Dec 16, 2022	williams eugene	bought	9,290	4.645	2,000	-
Dec 15, 2022	kirwin patrick d.	bought	9,020	4.51	2,000	-
Dec 14, 2022	farfel gail m	bought	4,940	4.94	1,000	chief executive officer
Dec 13, 2022	kirwin patrick d.	bought	4,870	4.87	1,000	-
Dec 12, 2022	williams eugene	bought	5,075	5.075	1,000	-

Which funds bought or sold PMN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 29, 2024	Claret Asset Management Corp	unchanged	-	9,000	21,000	-%
Apr 26, 2024	Hara Capital LLC	new	-	56,185	56,185	0.03%
Feb 15, 2024	SPHERA FUNDS MANAGEMENT LTD.	unchanged	-	-1,577,280	2,109,150	0.34%
Feb 14, 2024	Royal Bank of Canada	unchanged	-	-	1,000	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	-1,383	1,916	-%
Feb 14, 2024	Ally Bridge Group (NY) LLC	added	100	173,324	1,226,680	0.73%
Feb 14, 2024	AllSquare Wealth Management LLC	unchanged	-	-153	213	-%
Feb 14, 2024	Northeast Financial Consultants Inc	unchanged	-	-83,030	115,000	0.01%
Feb 13, 2024	Affinity Asset Advisors, LLC	unchanged	-	-220,825	305,852	0.06%

Are Funds Buying or Selling PMN?

Are funds buying PMN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PMN

No. of Funds

Unveiling ProMIS Neurosciences, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 05, 2024	sphera funds management ltd.	9.99%	1,892,474	SC 13G/A
Jan 02, 2024	sclar jeremy m.	17.4%	3,581,701	SC 13G/A
Dec 27, 2023	gordon michael s	12.5%	2,534,877	SC 13G/A

Recent SEC filings of ProMIS Neurosciences, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 30, 2024	8-K	Current Report
Apr 25, 2024	DEFA14A	DEFA14A
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	ARS	ARS
Apr 01, 2024	8-K	Current Report
Apr 01, 2024	424B5	Prospectus Filed
Apr 01, 2024	10-K	Annual Report
Feb 05, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to ProMIS Neurosciences, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

ProMIS Neurosciences, Inc. News

Latest updates

ProMIS Neurosciences, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet										(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2020Q4
Assets	-23.8%	13,619	17,876	1,498	4,428	6,925	5,382	10,189	13,968	17,747	1,086
Current Assets	-23.7%	13,619	17,858	1,479	4,409	6,903	5,359	10,162	-	17,714	973
Cash Equivalents	-25.3%	12,598	16,868	1,223	3,332	5,876	3,921	8,904	13,754	16,944	807
Net PPE	-	-	-	-	-	321*	788*	3.00	-	5.00	78.00
Liabilities	-11.3%	9,866	11,121	10,026	10,607	8,272	4,652	3,479	7,783	12,087	1,883
Current Liabilities	-5.1%	9,350	9,851	8,739	8,706	6,413	3,099	1,874	-	929	1,883
Shareholder's Equity	-44.4%	3,753	6,755	-	-	-1,347	730	6,710	3,738	5,660	-
Retained Earnings	-4.0%	-93,465	-89,900	-87,524	-85,200	-80,253	-72,987	-67,031	-	-62,191	-52,401
Additional Paid-In Capital	0.6%	97,590	97,012	79,368	79,234	79,101	73,988	73,879	-	68,039	51,655
Shares Outstanding	1.9%	18,885	18,525	8,579	8,579	8,579	7,196	7,196	7,196	7,196	4,829

Cashflow (Last 12 Months)

(In )

Cashflow (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Cashflow From Operations	-58.1%	-3,758,238	-2,376,462	-2,147,322	-2,561,654	-4,553,628	-4,635,698	-4,477,789	-3,366,768	-4,046,680	-3,030,266	-	-
Share Based Compensation	-	4,841	-	134,191	132,510	138,004	108,584	116,943	124,865	118,149	189,629	126,264	-
Cashflow From Investing	-	-	-	-	-	43.00	24.00	9.00	-2,057	95,805	-3,559	-	-
Cashflow From Financing	-Infinity%	-510,614	-	-	-	-	-	-	-	445	18,639,825	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PMN Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 7,883,165	$ 16,087,168
General and administrative	6,379,568	7,292,744
Total operating expenses	14,262,733	23,379,912
Loss from operations	(14,262,733)	(23,379,912)
Other income (expense):
Change in fair value of financial instruments	866,738	4,176,767
Other interest expense	(201,390)
Interest expense on convertible debt		(282,064)
Gain on extinguishment of convertible debt and derivative liability		1,307,421
Other income	384,903	115,525
Total other income (expense), net	1,050,251	5,317,649
Net loss	(13,212,482)	(18,062,263)
Other comprehensive loss
Foreign currency translation adjustment		(7,450)
Comprehensive loss	$ (13,212,482)	$ (18,069,713)
Net loss per share, basic	$ (1.07)	$ (2.41)
Net loss per share, diluted	$ (1.07)	$ (2.41)
Weighted-average shares outstanding of common shares, basic	12,292,707	7,502,609
Weighted-average shares outstanding of common shares, diluted	12,292,707	7,502,609

PMN Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash	$ 12,598,146	$ 5,875,796
Short-term investments	32,358	31,009
Prepaid expenses and other current assets	988,641	996,682
Total current assets	13,619,145	6,903,487
Property and equipment, net		321
Intangible assets, net		20,838
Total assets	13,619,145	6,924,646
Current liabilities:
Accounts payable	7,843,136	2,975,398
Accrued liabilities	1,506,526	3,437,646
Total current liabilities	9,349,662	6,413,044
Share-based compensation liability	422,002
Warrant liability	94,185	1,859,374
Total liabilities	9,865,849	8,272,418
Commitments and contingencies (Note 16)
Shareholders' equity (deficit):
Additional paid-in capital	97,590,426	79,101,061
Accumulated other comprehensive loss	(371,184)	(195,369)
Accumulated deficit	(93,465,946)	(80,253,464)
Total shareholders' (deficit) equity	3,753,296	(1,347,772)
Total liabilities and shareholders' (deficit) equity	13,619,145	6,924,646
Series 1 Preferred Shares [Member]
Shareholders' equity (deficit):
Convertible preferred stock

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

CEO	Dr. Gail M. Farfel Ph.D.
WEBSITE	promisneurosciences.com
INDUSTRY	Biotechnology
EMPLOYEES	6

ProMIS Neurosciences, Inc. Frequently Asked Questions

What is the ticker symbol for ProMIS Neurosciences, Inc.? What does PMN stand for in stocks?

PMN is the stock ticker symbol of ProMIS Neurosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ProMIS Neurosciences, Inc. (PMN)?

As of Thu May 02 2024, market cap of ProMIS Neurosciences, Inc. is 37.73 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PMN stock?

You can check PMN's fair value in chart for subscribers.

What is the fair value of PMN stock?

You can check PMN's fair value in chart for subscribers. The fair value of ProMIS Neurosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ProMIS Neurosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PMN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ProMIS Neurosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether PMN is over valued or under valued. Whether ProMIS Neurosciences, Inc. is cheap or expensive depends on the assumptions which impact ProMIS Neurosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PMN.